Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06092216 · ClinicalTrials.gov registry record · Phase 2
Spesolimab in Pyoderma Gangrenosum
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT06092216 is a Phase 2 study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 5 participants.
The verdict
NCT06092216, a Phase 2 study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this research study is to assess the feasibility of using spesolimab in participants with moderate to severe pyoderma gangrenosum. Pyoderma gangrenosum is a rare, inflammatory, autoimmune condition which results in ulceration of skin. The study will also investigate the body's immune response to the spesolimab (when the body detects and defends itself against substances that appear unknown and harmful).
Interventions
- DRUG Spesolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-09-23 |
| Est. Completion | 2025-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06092216
The ClinicalTrials.gov registry entry for NCT06092216 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Spesolimab is the first listed.
NCT06092216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06092216 about?
NCT06092216 is a clinical study titled "Spesolimab in Pyoderma Gangrenosum". The purpose of this research study is to assess the feasibility of using spesolimab in participants with moderate to severe pyoderma gangrenosum. Pyoderma gangrenosum is a rare, inflammatory, autoimmune condition which results in ulceration of skin. The study will also investigate the body's immune ...
What is the current status of trial NCT06092216?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2023-09-23. Estimated completion is 2025-01-14.
What interventions are being tested in trial NCT06092216?
The interventions under investigation include: Spesolimab (DRUG).
Who is sponsoring clinical trial NCT06092216?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.